The correlation between HIGD1B and the clinicopathological parameters of gastric cancer was then evaluated, and it was discovered that there was no statistically significant variance in HIGD1B expression among age, gender, N and M staging populations (Figures 2D, E, I, J), but that there was higher expression of HIGD1B in the death population (fustat=1), higher pathological grade (G3), later stage and T stage groups (Figures 2C, F–H). Here, HIGD1B is linked to gastric cancer.